Company Profile

Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.

Employees

Sector

Biotechnology & Medical Research

More about the company

19/10/22	Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022	CI
13/07/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index	CI
12/07/22	Innoviva Acquires Remaining Stake in Entasis Therapeutics	MT
11/07/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index	CI
11/07/22	Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.	CI
24/06/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index	CI
24/06/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index	CI
23/05/22	Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell	MT
17/05/22	Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference	CI
06/05/22	Cantor Fitzgerald Downgrades Entasis Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $2 From $5	MT
28/04/22	Wedbush Lifts Price Target on Entasis Therapeutics Holdings to $2 From $1.80 on Innoviva's Revised Bid, Maintains Neutral Rating	MT
27/04/22	Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
26/04/22	Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference	CI

06/05/22	Cantor Fitzgerald Downgrades Entasis Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $2 From $5	MT
28/04/22	Wedbush Lifts Price Target on Entasis Therapeutics Holdings to $2 From $1.80 on Innoviva's Revised Bid, Maintains Neutral Rating	MT
16/03/22	Alliance Global Downgrades Entasis Therapeutics Holdings to Neutral From Buy	MT
08/03/22	Wedbush Cuts Entasis Therapeutics Holdings to Neutral From Outperform, Price Target to $1.80 From $9, Citing Acquisition Proposal	MT
05/03/22	HC Wainwright Downgrades Entasis Therapeutics Holdings to Neutral from Buy, Adjusts Price Target to $1.80 from $6	MT

12/07/22	Entasis Therapeutics : Termination of a Material Definitive Agreement - Form 8-K	PU
12/07/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
10/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	AQ
09/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	GL
24/05/22	Entasis Therapeutics : Innoviva to Acquire Entasis Therapeutics - Form 8-K	PU

Manager	Title	Age	Since
Pavel Raifeld PSD	President	42	11/07/2022
David Altarac CTO	Chief Tech/Sci/R&D Officer	65	04/11/2019
Ruben Tommasi CTO	Chief Tech/Sci/R&D Officer	60	01/05/2015

Director	Title	Age	Since
Heather Behanna BRD	Director/Board Member	51	01/08/2017
David Hastings BRD	Director/Board Member	64	01/04/2018
Heather Preston BRD	Director/Board Member	60	01/08/2017

Entasis Therapeutics Holdings Inc. Stock

Stocks

ETTX

US2936141033

Biotechnology & Medical Research

Latest news: Entasis Therapeutics Holdings Inc.

Analysts' recommendations: Entasis Therapeutics Holdings Inc.

Press Releases: Entasis Therapeutics Holdings Inc.

Quotes and Performance

Managers and Directors: Entasis Therapeutics Holdings Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/7/22	Kristie Wagner	Issuer sale	Chief Financial Officer	153,900	0.3216%
11/7/22	Anna Diaz Triola	Issuer sale	Executive/Senior Manager	225,000	0.4702%
8/7/22	INNOVIVA, INC.	Buy	Company	19,270,476	40.2712%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTASIS THERAPEUTICS HOLDINGS INC.	-0.45%	-.--%	-	-	105M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+47.13%	+99.00%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	+2.12%	-5.86%	+161.58%	+329.34%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.24B
Average	-0.24%	+1.74%	+36.57%	+208.32%	30.54B
Weighted average by Cap.	-0.28%	+1.49%	+35.68%	+148.22%